Be The Match BioTherapies to present at Cell Therapy Manufacturing & Gene Therapy Congress on Dec. 6
MINNEAPOLIS – Nov. 2017
Be The Match BioTherapies® will be participating in the Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam, Dec. 6-7, 2017.
On Wednesday, Dec. 6 at 12:25 p.m., Amy Ronneberg, MBA, president of Be The Match BioTherapies, will present “Navigating the cell therapy supply chain – when exceptions are the norm,” as part of the Clinical Development for Cell, Gene and Immunotherapies stream.
Her discussion will focus on the complexities of the cell therapy supply chain and strategies for mitigating risk to successfully deliver therapies to patients in need. Throughout the last 30 years, Be The Match BioTherapies’ parent company, the National Marrow Donor Program (NMDP)/Be The Match has successfully managed more than 80,000 stem cell transplants. Based on this experience, the organization has learned that a successful cell therapy delivery needs the dedication of patient and therapy management staff, in addition to the support of a proven technology platform.
Ronneberg is also the Chief Financial Officer of Be The Match BioTherapies’ parent company, NMDP/Be The Match.